Abstract
It has been suggested that one means by which chemotherapeutic agents exert their effect on leukaemic cells, is via autocrine induction of fas-ligand which then binds to fas (CD95), activates the caspase pathway and results ultimately in apoptotic death. In order to test this hypothesis, we have treated leukaemic cell lines with various chemotherapeutic agents (idarubicin, etoposide, fludarabine and 2-CdA) with and without pre-treatment with fas (ZB4) and fas-ligand (NOK-1) blocking monoclonal antibodies. Cell cycle analysis and quantitation of apoptosis were performed by flow cytometry following propidium iodide staining. HL-60 cells were found to be sensitive to the induction of apoptosis with all drugs tested but were highly resistant to treatment with a fas-ligating antibody (CH11). Apoptosis was neither inhibited in parental CEM cells nor their mdr-expressing drug resistant counterpart, CEM/VLB100 by pre-treatment with either ZB4 or NOK1. In addition, CEM/VLB100 were slightly more sensitive to treatment with CH11 (100ng/ml) than parental CEM cells (% age apoptosis = 30.35 and 23.675, p=0.024) and at least as sensitive to recombinant fas-ligand (50 ng/ml) (% age apoptosis = 26.6 and 20.2, p=NS).
We conclude that it is unlikely that fas/fas-ligand interactions play a significant role in the induction of apoptosis by these chemotherapeutic agents in the leukaemic cell lines tested.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dive C, Wyllie AH. Apoptosis and cancer chemotherapy. In: Hickman JA, Tritton TR, eds. Cancer Chemotherapy. Oxford: Blackwell Scientific Publications; 1993:21–55.
Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death?. Br J Cancer. 1991, 64, 192–196.
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993, 53(17), 3976–3985.
Nagata S. Apoptosis by death factor. Cell. 1997, 88, 355–365.
Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B, Fath M, Daniel PT, Knipping E, Westendorp MO, Stricker K, Bäumler C, Hellbardt S, Germer M, Peter ME, Debatin K-M. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev. 1994, 142, 175–191.
Schlegel J, Peters I, Orrenius S, Miller DK, Thornberry NA, Yamin TT, Nicholson DW. CPP32/apopain is a key interleukin 1 beta converting enzyme-like protease involved in Fas-mediated apoptosis. J Biol Chem. 1996, 271(4), 1841–1844.
Hasegawa J, Kamada S, Kamiike W, Shimizu S, Imazu T, Matsuda H, Tsujimoto Y. Involvement of CPP32/Yama(-like) proteases in Fas-mediated apoptosis. Cancer Res. 1996, 56(8), 1713–1718.
Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (fas/APO-1)-mediated T cell apoptosis. J Exp Med. 1996, 184,765–770.
Debatin K-M, Goldmann CK, Bamford R, Waldmann TA, Krammer PH. Monoclonal antibody-mediated apoptosis in adult T-cell leukaemia. Lancet. 1990, 335, 497–500.
Debatin K-M, Goldmann CK, Waldmann TA, Krammer PH. APO-1-induced apoptosis of leukemia cells from patients with adult T-cell leukemia. Blood. 1993, 81, 2972–2977.
Nonomura N, Miki T, Yokoyama M, Imazu T, Takada T, Takeuchi S, Kanno N, Nishimura K, Kojima Y, Okuyama A. Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Biochem Biophys Res Commun. 1996, 229, 945–951.
Friesen C, Herr I, Kramer PH, Debatin K-M. Involvement of the CD95 (APO-1/Fas) receptor/1 igand system in drug-induced apoptosis in leukemia cells. Nature Med. 1996, 2, 574–577.
Beck WT, Mueller TJ, Tanzer LR. Altered surface membrane glycoproteins in vinca alkaloid-resistant human leukemic lymphoblasts. Cancer Res. 1979, 39(6),2070–2076.
Kartner N, Riordan JR, Ling V. Cell surface p-glycoprotein is associated with multidrug resistance in mammalian cell lines. Science. 1983, 221, 1285–1288.
Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992, 13, 795–808.
Muller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest. 1997, 99(3), 403–413.
Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofier R, Greil R. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells. Cancer Res. 1997, 57(16), 3331–3334.
Tewari M, Dixit M. Fas-and tumour necrosis factor-induced apoptosis is inhibited by the cowpox virus crmA gene product. J Biol Chem. 1995, 270, 3255–3260.
Gamen S, Anel A, Lasierra P, Alava MA, Martinezlorenzo MJ, Pineiro A, Naval J. Doxorubicin-induced apoptosis in human T-cell leukemia is mediated by caspase-3 activation in a fas-independent way. FEBS Lett. 1997, 417(3), 360–364.
Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ, Kaufmann SH. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood. 1997, 90(3), 935–943.
Dirks W, Schöne S, Uphoff C, Quentmeier H, Pradella S, Drexler HG. Expression and function of CD95 (fas/apo-1) in leukaemia-lymphoma tumour lines. Br J Haematol. 1997, 96, 584–593.
Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA. 1985, 82, 790–794.
Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to fas-mediated apoptosis. Blood. 1997, 89(6), 1854–1861.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Richardson, D.S., Allen, P.D., Kelsey, S.M., Newland, A.C. (1999). Inhibition of FAS/FAS-Ligand Does Not Block Chemotherapy-Induced Apoptosis in Drug Sensitive and Resistant Cells. In: Kaspers, G.J.L., Pieters, R., Veerman, A.J.P. (eds) Drug Resistance in Leukemia and Lymphoma III. Advances in Experimental Medicine and Biology, vol 457. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4811-9_28
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4811-9_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7180-9
Online ISBN: 978-1-4615-4811-9
eBook Packages: Springer Book Archive